Article

Hypercholesterolemia Treatment Granted FDA Priority Review

Sanofi and Regeneron Pharmaceuticals recently announced that the FDA has accepted for priority review a Biologics License Application for their investigational drug, alirocumab, which is indicated for patients with hypercholesterolemia.

Sanofi and Regeneron Pharmaceuticals recently announced that the FDA has accepted for priority review a Biologics License Application (BLA) for their investigational drug, alirocumab (Praluent), which is indicated for patients with hypercholesterolemia.

The FDA’s goal for completing its priority review of Praluent is 6 months, with a target action date set for July 24, 2015.

The BLA for Praluent contains data from more than 5000 patients, including the participants of 10 phase 3 trials. In total, the Odyssey clinical trial program evaluating Praluent will enroll more than 23,500 patients at more than 2000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years.

Sanofi and Regeneron reported positive results from 2 of those trials earlier this month.

To date, no regulatory authority has fully evaluated the safety and efficacy of Praluent, a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com